{"paper_id":"8c358238-a744-455d-b2ab-9e70a1f9b063","body_text":"Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.\nSerum YKL-40 levels as a novel marker of inflammation in patients with endometriosis\nAffiliations\nArticle Info\n1 Recep Tayyip Erdoğan University School of Medicine, Department of Obstetrics & Gynecology, Rize\n2 Recep Tayyip Erdoğan University School of Medicine, Department of Biochemistry, Rize (Turkey)\nAbstract\nPurpose: To establish serum YKL-40 concentrations in patients with endometriosis compared to age-matched healthy subjects. Materials and Methods: This was a cross-sectional clinical study conducted in a tertiary care center. Demographics and serum YKL levels were determined and noted in a total of 63 cases (33 endometriosis patients, 30 healthy controls). Measurement of YKL-40 levels was made using a YKL-40 enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s protocol. Results: The mean serum YKL-40 levels of the patient group was 106.0 ± 15.9 (range 23.44 to 382.55) years, while the mean serum YKL-40 levels of the controls was 52.2 ± 7.0 (range 22.35 to 160.0) years (p = 0.003). Conclusions: This is the first study evaluating serum YKL-40 levels in endometriosis. The present results indicate that YKL-40 levels were increased in patients with endometriosis compared to controls. The authors propose that circulating YKL-40 levels could be a novel biomarker for diagnosis and follow-up of endometriosis.\nKeywords\n- Endometriosis\n- Serum\n- YKL-40 levels\n- Marker","source_license":"CC0","license_restricted":false}